---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Limitations of current therapies"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Limitations of current therapies. Topics: Summary: limitations of current therapies, No approved disease-directed therapy, Progression despite blood pressure control and RAS inhibition, and Residual disease burden and treatment utilization in real-world AMKD. 4 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Limitations of current therapies

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

### Summary: limitations of current therapies

No therapy directed at APOL1-mediated kidney disease is approved; the KDIGO 2025 conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”, and a 2021 Delphi consensus agreed that “No specific treatment is currently available”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, the primary kidney outcome occurred in 58.1% of participants with a high-risk genotype and 36.6% of those with a low-risk genotype (hazard ratio 1.88), with no interaction between APOL1 status and the randomized blood-pressure goal or antihypertensive drug. In the FSGS Clinical Trial, APOL1 genotype did not affect proteinuria response to cyclosporine or mycophenolate mofetil with dexamethasone, but participants with the high-risk genotype were more likely to progress to ESRD. In DUPLEX, sparsentan reduced proteinuria more than irbesartan without a significant difference in eGFR slope at 108 weeks, and the APOL1 high-risk subgroup comprised 14 participants. In a real-world cohort of 1,332 people with AMKD, 35.7% had a RAAS inhibitor fill or administration and 10.5% an SGLT2 inhibitor, and 45.7% had CKD stage 4 or 5.

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/); [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/); [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/); [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/); [Rheault et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37921461/); [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/); [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs); [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf); [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.9-2"></a>

### No approved disease-directed therapy

> “There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “A24. No specific treatment is currently available for patients with APOL1-associated nephropathy”
> “There is currently no specific treatment or management protocol for APOL1-associated nephropathy, and so, the clinical value of APOL1 testing in routine clinical practice has not been established.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Although there is currently no approved treatment for AMKD, multiple therapeutic trials are ongoing.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “There are no therapies currently approved for AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.1.9-3"></a>

### Progression despite blood pressure control and RAS inhibition

> “In conclusion, renal high-risk variants in APOL1 were associated with an increased risk of progression of chronic kidney disease among black patients, even among those with well-controlled blood pressure.”
> “Currently, therapeutic options to retard disease progression are limited.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

> “As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.1.9-4"></a>

### Residual disease burden and treatment utilization in real-world AMKD

> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”
> “Variable treatment utilization and substantial residual disease burden underscore the significant unmet need for targeted therapies that address the underlying disease pathophysiology,”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
